ClinicalTrials.Veeva

Menu

Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ (GerdQ-Greece)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Gastroesophageal Reflux Disease

Study type

Observational

Funder types

Industry

Identifiers

NCT00914342
NIS-GGR-DUM-2009/1

Details and patient eligibility

About

The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire. Furthermore the study aims to estimate GERD prevalence in patients based on their symptoms as they respond to a physician's questionnaire, to observe possible variations between the two methods (physicians' symptom rating and GerdQ), to objectively measure treatment response and to identify the percentage of patients that may require alterations of their treatment. Finally, to describe the impact of GERD symptoms on work productivity.

Enrollment

889 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with upper-GI symptoms the last week prior visiting the investigator

Exclusion criteria

  • History of oesophageal, gastric or duodenal surgery
  • Treatment with NSAIDs/Acetylsalicylic acid within the last week prior to the study visit
  • PPI use for healing of NSAIDs induced ulcer or for HP eradication

Trial design

889 participants in 1 patient group

Upper-GI symptoms in primary-care patients

Trial contacts and locations

54

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems